Relutrigine

Relutrigine
Clinical data
Other names	PRAX-562; PRAX562
Routes of; administration	Oral
Drug class	Sodium channel blocker; Anticonvulsant
Identifiers
	IUPAC name 3-[ethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-[1,2,4]triazolo[4,3-a]pyrazine;
CAS Number	2392951-29-8;
PubChem CID	147075611;
DrugBank	DB21614;
ChemSpider	115277038;
UNII	AW5C5XHM4W;
ChEMBL	ChEMBL5314479;
Chemical and physical data
Formula	C15H11F6N5O2
Molar mass	407.276 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(C1=NN=C2N1C=C(N=C2)C3=CC(=C(N=C3)OCC(F)(F)F)F)(F)F;
	InChI InChI=1S/C15H11F6N5O2/c1-2-28-15(20,21)13-25-24-11-5-22-10(6-26(11)13)8-3-9(16)12(23-4-8)27-7-14(17,18)19/h3-6H,2,7H2,1H3; Key:BFXBSYMVTNEFRF-UHFFFAOYSA-N;

Relutrigine (INNTooltip International Nonproprietary Name; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache.^[1]^[2]^[3] It is taken orally.^[1] The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers.^[2]^[3] Relutrigine is under development by Praxis Precision Medicines.^[1]^[2] As of May 2026, it is in preregistration for epilepsy.^[1] Conversely, no recent development has been reported for headaches.^[1]

References

^ ^a ^b ^c ^d ^e ^f "Praxis-Precision-Medicines". AdisInsight. 19 May 2026. Retrieved 6 June 2026.
^ ^a ^b ^c Müller P, Draguhn A, Egorov AV (October 2024). "Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers". Pflugers Archiv. 476 (10): 1445–1473. doi:10.1007/s00424-024-02980-7. PMC 11381486. PMID 38967655.
^ ^a ^b Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. (March 2022). "The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers". Epilepsia. 63 (3): 697–708. doi:10.1111/epi.17149. PMC 9304232. PMID 35037706.

[AdisInsight-1] ^ ^a ^b ^c ^d ^e ^f "Praxis-Precision-Medicines". AdisInsight. 19 May 2026. Retrieved 6 June 2026.

[MüllerDraguhnEgorov2024-2] Müller P, Draguhn A, Egorov AV (October 2024). "Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers". Pflugers Archiv. 476 (10): 1445–1473. doi:10.1007/s00424-024-02980-7. PMC 11381486. PMID 38967655.

[KahligScottHatch2022-3] Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. (March 2022). "The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers". Epilepsia. 63 (3): 697–708. doi:10.1111/epi.17149. PMC 9304232. PMID 35037706.

[1]

[2]

[3]

See also

References